Liposomes always require lots of phospholipid -- and in fact, to ensure good results, a great excess of phospholipid often needs to be used. It's also an expensive process, and one that generally results in liquid formulations. Unless the potential for bioavailability enhancement is truly extraordinary, I don't think that liposomal formulations are worth the added expensive, as a rule. In this particular case, any potential gains would likely be mild, and, as a commercial product, it wouldn't be feasible.
UA products are a tough sell these days, in general.
I'll see what I can do about offering a standalone cyclo-UA or arginine ursolic acetate product, though. If it looks worthwhile, I'll add it to the list. (Though, admittedly, it's quite a long list already! Lots of cool stuff in the works!)